miR-34a-5p was also identified to target specific cancer types; including colorectal cancer, thyroid cancer, non-small cell lung cancer, chronic myeloid leukemia, bladder cancer, pancreatic cancer, glioma, and melanoma, in addition to multiple cancer-related pathways as cell cycle, pathways in cancer, p53 signaling pathway, and proteoglycans in cancer. This evidence concerns the gene TP53 and chronic myelogenous leukemia, BCR-ABL1 positive.